Zai Lab Limited — Board/Management Information 2022

Apr 3, 2022

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [99 x 51] intentionally omitted <==

**Zai Lab Limited 再鼎醫藥有限公司 ***

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

OVERSEAS REGULATORY ANNOUNCEMENT

We are making this announcement pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

We filed a Form 8-K on April 1, 2022 (U.S. Eastern Time) with the Securities and Exchange Commission of the United States to announce that Tao Fu, Chief Strategy Officer of Zai Lab Limited (the “ Company ”), provided notice to the Company of his resignation from the Company on March 28, 2022, effective as of the close of business on April 8, 2022. There were no disagreements between Mr. Fu and the Company relating to the Company’s operations, policies or practices that resulted in Mr. Fu’s resignation. For further details of our filing, please refer to the attached Form 8-K.

By order of the Board Zai Lab Limited Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, April 3, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison and Mr. Richard Gaynor as the independent directors.

• For identification only

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 28, 2022

ZAI LAB LIMITED

(Exact name of registrant as specified in its charter)

Cayman Islands

(State or other jurisdiction of incorporation or organization)

001-38205

(Commission File Number)

98-1144595

(I.R.S. Employer Identification No.)

4560 Jinke Road

Bldg. 1, Fourth Floor Pudong Shanghai, China

(Address of principal executive offices)

201210 (Zip Code)

+86 21 6163 2588

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

• ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

• ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

• ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

• ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(b) of the	Act:
Title of each classAmerican Depositary Shares, each representing10 Ordinary Share, par value $0.000006 pershareOrdinary Shares, par value $0.000006 pershare*	TradingSymbol(s)ZLAB9688	Name of each exchangeon which registered
		The Nasdaq Global MarketThe Stock Exchange of Hong Kong Limited

•    Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited 
  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 28, 2022, Tao Fu, Chief Strategy Officer of Zai Lab Limited (the “Company”), provided notice to the Company of his resignation from the Company, effective as of the close of business on April 8, 2022. There were no disagreements between Mr. Fu and the Company relating to the Company’s operations, policies or practices that resulted in Mr. Fu’s resignation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZAI LAB LIMITED

By: /s/ Samantha Du Samantha Du Chief Executive Officer

Date: April 1, 2022